Dialysis News and Research

Latest Dialysis News and Research

Study reveals how geography affects the survival of people with end-stage kidney disease

The notion that geography often shapes economic and political destiny has long informed the work of economists and political scholars. Now a study led by medical scientists at Johns Hopkins reveals how geography also appears to affect the very survival of people with end-stage kidney disease in need of dialysis.

24 Jun 2015

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.

24 Jun 2015

EMS Find inks LOI to acquire Page Out

EMS Find, Inc. today announced that the company has signed a Letter Of Intent ("LOI") to acquire Page Out – interactive platform designed to streamline the emergency response process and provides management with real time status on where and when team members are responding to emergency and dispatch.

23 Jun 2015

Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

NxStage Medical, Inc. is encouraging patients to take control of their dialysis therapy and consider home hemodialysis in the wake of a new study that found patient survivability rates are significantly higher with home hemodialysis (HHD) than peritoneal dialysis (PD).

18 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

Link between poverty and kidney disease changes over time, shows study

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time.

17 Jun 2015

Link between poverty and kidney disease changes over time, study finds

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time.

16 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

DaVita Kidney Care releases list of top 10 U.S. travel destinations for dialysis patients

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today released a list of the top 10 U.S. travel destinations for dialysis patients.

3 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress.

2 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.

28 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

WHO is also providing a shipment of anti-malaria medicines from the Global Fund to Fight AIDS, Tuberculosis and Malaria sufficient for 44 950 treatment courses of malaria...

15 May 2015

DaVita HealthCare Partners recognizes May as Employee Health Month

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, recognizes the month of May as Employee Health Month. The health of teammates is vital in helping to ensure they can provide the best quality of care for DaVita HealthCare Partners' patients.

7 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015

Dialysis News and Research

Latest Dialysis News and Research

Study reveals how geography affects the survival of people with end-stage kidney disease

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

EMS Find inks LOI to acquire Page Out

Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Link between poverty and kidney disease changes over time, shows study

Link between poverty and kidney disease changes over time, study finds

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

DaVita Kidney Care releases list of top 10 U.S. travel destinations for dialysis patients

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

First European approval of drug to treat genetic kidney disease ADPKD

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

DaVita HealthCare Partners recognizes May as Employee Health Month

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Dialysis News and Research

Latest Dialysis News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in